Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
We are now building upon this success and have launched a new, significant fundraising campaign. This campaign will help drive further transformational growth, from income across major donors, trusts and foundations, and corporate partners. Ultimately, it will help us fund cutting-edge research that will bring forward the day when we can diagnose, treat and prevent dementia.
Astex Pharmaceuticals is a world leader in innovative drug discovery and development. The company has successfully applied its proprietary Fragment-Based Drug Discovery platform to generate multiple new drug candidates that are progressing in clinical development. Successful collaborations have led to three launched oncology drugs (Kisqali® partnered with Novartis, Balversa® partnered with Janssen and Truqap™ partnered with AstraZeneca). Astex continues to grow and focuses on Neurological Disorders and Oncology.
The Role
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
About Healx
Healx is an AI-powered tech bio company redesigning drug discovery. With over 10,000 rare diseases affecting 400 million people globally - and 90% lacking approved treatments - our mission is to pioneer a new generation of drug discovery to bring treatments to patients faster.
We combine data, artificial intelligence and deep pharmacology expertise to develop therapies more efficiently and cost-effectively than traditional approaches.
Open to all scientists researching new therapeutics in Cambridge and the local area.
The purpose of the CamNTF forum is to promote interactions between scientists from academia & industry in order to improve opportunities for biotechnology research and development. Meeting attendance is free but all attendees must register in advance.
The evening cocktail reception at Australia House in London will provides direct access to biotech stakeholders within the city’s thriving ecosystem. This networking event will highlight high-value collaboration opportunities by showcasing the Australia as a global leading destination for conducting efficient and cost-effective clinical trials. To further group these connections, the session will be complemented by supplemental site visits within the city biotech ecosystem.
Fast growing techbio: data, computational research, IP and how to leverage those for commercial success
Join us for a panel discussion and networking event at our new London office and hear from people with a passion for techbio.
We're bringing together key stakeholders from across the ecosystem, and they'll be sharing invaluable insights and experiences crucial for success.
Our discussion will encompass topics such as:
About us:
LifeArc is a not-for-profit life science organisation, leading the way for change in rare diseases in the UK and supporting promising initiatives in global health. We seek out research in areas of unmet need that has great potential, providing support to help it become breakthroughs that change lives.
About the role: